Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by an educational grant from Pfizer, Inc.
Community Practice Connections™: Real World Scenarios and Applications for Biosimilars in HER-Positive Breast Cancer: Key Concepts for Clinical Decision Making
Release Date: May 07, 2020
Expiration Date: May 07, 2021
Activity Overview
This online education activity is designed to provide expert commentary regarding the required scientific rigor necessary for the biosimilar development and approval process. This program includes clinical data supporting the use of recently approved anti-HER2 monoclonal antibody biosimilars currently available for breast cancer treatment and reviews best practices for incorporating biosimilars into clinical practice. This activity is presented in a multimedia format that includes a series of video interviews with expert thought leaders integrated into text-based elements.
Acknowledgement of Support
This activity is supported by an educational grant from Pfizer, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational activity is directed toward medical oncologists who treat patients with breast cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer are also invited to participate.
Learning Objectives
Upon successful completion of this educational activity, you should be better prepared to:
- Describe the comprehensive set of preclinical and clinical data required to demonstrate the comparability of a biosimilar with its reference product
- Discuss clinical data supporting approved and emerging biosimilar agents in the treatment of HER2-positive breast cancer
- Assess clinician concerns and challenges regarding efficacy and safety of biosimilars as they are integrated into clinical practice
- List pharmacovigilance considerations for biosimilars in the United States and ensure familiarity with safety and efficacy data of biosimilar products
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Faculty
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, CA
Disclosures: Grant Research Support: Daiichi Sankyo, Eisai, Eli Lilly, Genentech, Immunomedics, MacroGenics, Merck, Novartis, OBI Pharma, Odonate Therapeutics, Pfizer, Seattle Genetics; Travel: Amgen, AstraZeneca, Daiichi Sankyo, MacroGenics, Merck, Mylan, Pfizer, Puma Biotechnology.
Professor of Medicine
Associate Chief, Division of Hematology/Oncology
Co-Director, Comprehensive Breast Cancer Center
UPMC Hillman Cancer Center
UPMC Magee-Women’s Hospital
University of Pittsburgh Medical Center
Pittsburgh, PA
Disclosures: Grant Research Support: Agendia, Bioarray, Biotheranostics, Celgene, Eisai, Eli Lilly, Genomic Health, NanoString Technologies, Novartis, Pfizer, Roche.
Oncology Resident Director, Ambulatory Pharmacy Services
Clinical Oncology Pharmacist, Ambulatory Pharmacy Services
Team Leader, Ambulatory Pharmacy Services
UI Health
Clinical Associate Professor, Pharmacy Practice
The University of Illinois at Chicago College of Pharmacy
Chicago, IL
Disclosures: Speakers Bureau: Coherus, Eisai; Other: Advisory Board: Coherus.
Director, Breast Cancer Clinic
Co-Director, Santa Monica – UCLA Outpatient Hematology/Oncology Practice Associate Professor of Medicine, Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Santa Monica, CA
Disclosures: Grant Research Support: Ambrx, Amgen, Arvinas, Bayer, Cascadian Therapeutics, Daiichi Sankyo, Dignitana, Eli Lilly, Genentech, GlaxoSmithKline, Immunomedics, MacroGenics, Medivation, Merrimack Pharmaceuticals, Novartis, OBI Pharma, Pfizer, Pieris Pharmaceuticals, Puma Biotechnology, Radius, Roche, Seattle Genetics; Travel: Eli Lilly, Novartis, OBI Pharma.
The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
